MGMT and glioblastoma: We demonstrate that BETi specifically down regulates endogenous MGMT expression in GBM cells, sensitizing them to TMZ therapy, without compromising the mismatch repair (MMR) system that is essential for sensitivity to alkylating agent therapy [12, 13].